Futura Medical

is a research and development pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys® technology.

Our purpose is to enhance our patients and consumers’ quality of life through deep science to enable them to live their lives to the full.

Read more


  • Interview with Executive Director and Head of R&D - EU regulatory update and analysis of FM57

    Ken James speaks to Proactive Investor’s Andrew Scott following positive initial discussions with EU regulators after an extensive internal evaluation of the clinical data from the Phase 3 study (“FM57”).

View more videos

Read more

Share Price

Read more

Results, Reports and Presentations

AR 2018 Cover

Download our latest annual report 2018.

Read more

Our Products

Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain. Our late stage pipeline of products is based on our proprietary, transdermal DernaSys® technology designed to deliver clinically proven effective pharmaceutical treatments via the skin.

Read more


Lead product MED3000, is the only easy to use topical treatment for erectile dysfunction.

MED3000 which utilises our proprietary DermaSys® technology is a topical gel developed specifically for the treatment of erectile dysfunction (ED).

Read more


TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

Read more

DermaSys® Technology

Our unique patented transdermal DermaSys® technology  provides rapid and targeted local delivery clinically proven effective pharmaceutical treatment of via the skin. This versatile, clear, odourless gel provides effective and local topical application to the required site of action.

Read more

Investor Centre

Our investor centre includes all key investor information such as corporate documents, share price chart and the information required pursuant to AIM Rule 26.

Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

Read more

Our Strategy

Current therapeutic areas are sexual health and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst seeking to minimise risk.

Read more